Zobrazeno 1 - 10
of 26
pro vyhledávání: '"S. Sean Tu"'
Autor:
S. Sean Tu, Ameet Sarpatwari
Publikováno v:
New England Journal of Medicine. 388:483-485
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::baf758ca361a6ec558a922ae9919ac09
https://doi.org/10.1056/nejmp2216020
https://doi.org/10.1056/nejmp2216020
Publikováno v:
JAMA
Inhalers remain the cornerstone therapy for patients with asthma and chronic obstructive pulmonary disease (COPD). Over the past several decades, brand-name manufacturers have continued to sell most inhalers at high prices without the threat of direc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e22df1bfdd235cfe8d4325ced6f4989
http://eprints.lse.ac.uk/117798/
http://eprints.lse.ac.uk/117798/
Publikováno v:
IEEE pulse. 13(5)
The production of antibodies for therapeutic use in clinical medicine has become a focus of the biotechnology industry. In 2021, four of the top six selling prescription drugs were monoclonal antibodies, leading to a reported revenue of over US $ 67
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a377228ff6e3d03840987cefac693dc6
https://pubmed.ncbi.nlm.nih.gov/36301809
https://pubmed.ncbi.nlm.nih.gov/36301809
Product hops to albuterol inhalers containing hydrofluoroalkane rather than chlorofluorocarbons cost payers and patients billions of dollars. Without patent and regulatory reform, this pattern is likely to be repeated.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5907c6ca513746e585a46b90667bbe67
http://eprints.lse.ac.uk/116986/
http://eprints.lse.ac.uk/116986/
Publikováno v:
IEEE Pulse. 14:20-21
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a5245562cc51cc1f1dd2e207f32e5ae3
https://doi.org/10.1109/mpuls.2023.3243318
https://doi.org/10.1109/mpuls.2023.3243318
Publikováno v:
JAMA. 329:1641
This Viewpoint discusses a current Supreme Court lawsuit, Amgen v Sanofi, involving Amgen’s broad patents on PCSK9 that could effectively prevent other manufacturers from producing similar or even clinically superior antibodies, with important nega
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1fcc8c8a68b65b49ed25c244032b807d
https://doi.org/10.1001/jama.2023.5638
https://doi.org/10.1001/jama.2023.5638
Publikováno v:
JAMA. 329:1607
This study evaluates sales revenue earned in the first 5 years for newly marketed brand-name drugs with and without an initial orphan drug designation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ab053e1e7ef4e91aa88be1c7051a6dd
https://doi.org/10.1001/jama.2023.3079
https://doi.org/10.1001/jama.2023.3079
Publikováno v:
JAMA. 329:459
This Viewpoint discusses 3 bills introduced recently in Congress that focus on patent eligibility, fraud, and quality and that have major implications for clinical medicine and pharmaceutical development.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a379a42dde8ada1db32373fd801c7ca7
https://doi.org/10.1001/jama.2022.24983
https://doi.org/10.1001/jama.2022.24983
Autor:
Alexander C. Egilman, Victor L. Van de Wiele, Benjamin N. Rome, Jonathan J. Darrow, S. Sean Tu, Aaron S. Kesselheim, Ameet Sarpatwari
Publikováno v:
JAMA Internal Medicine. 183:82
This cohort study assesses the frequency of approval and marketing of skinny-label biosimilars and their savings to Medicare.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1d020c4d7e741fe9beab377acb0522fb
https://doi.org/10.1001/jamainternmed.2022.5419
https://doi.org/10.1001/jamainternmed.2022.5419